GlassScriptPhysician profile
Frank P Hull
NPI 1407832744
$89,886.18
in general payments reported to CMS, 2019-2025
59 companies · $1,915 in 2025
The $1,915 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $2,270 · 2021: $2,938 · 2022: $24K · 2023: $36K · 2024: $9,418 · 2025: $1,915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $41K · Food and Beverage: $5,661 · Education: $451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $41,140.50 |
| Food and Beverage | $5,660.58 |
| Education | $451.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $44,862.17 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $10,810.53 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Uk Limited | $10,627.00 | 2022 | |
| Insmed, INC. | $6,904.52 | 2020-2025 | Arikayce, Brinsupri |
| Intuitive Surgical, INC. | $4,055.55 | 2022-2024 | |
| Allergan, INC. | $1,860.53 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $1,820.68 | 2019-2025 | Uptravi, Opsumit |
| Mylan Specialty L.P. | $824.12 | 2019-2024 | Yupelri, Yupelri |
| Regeneron Healthcare Solutions, INC. | $727.62 | 2019-2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $697.23 | 2020-2024 | Acthar |
| Harmony Biosciences LLC | $611.27 | 2020-2023 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $600.87 | 2019-2025 | Ofev, Jascayd, Spiriva |
| Bayer Healthcare Pharmaceuticals INC. | $596.25 | 2019-2025 | |
| Paratek Pharmaceuticals, INC. | $428.97 | 2019-2024 | Nuzyra |
| Amgen INC. | $330.98 | 2022-2024 | Tezspire |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pinnacle Biologics, INC | $311.97 | 2021-2022 | |
| United Therapeutics Corporation | $302.24 | 2021-2025 | Tyvaso |
| Genzyme Corporation | $291.59 | 2019-2025 | |
| Astellas Pharma US INC | $288.92 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $282.60 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $253.52 | 2020-2025 | Glassia |
| Pfizer INC. | $250.91 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $185.19 | 2019-2025 | Winrevair |
| Viatris Specialty LLC | $144.15 | 2025 | Yupelri |
| Inspire Medical Systems, INC. | $133.45 | 2020 | |
| Grifols USA, LLC | $127.34 | 2019-2023 | Prolastin-C Liquid |
| Melinta Therapeutics, LLC | $125.20 | 2019-2023 | Rezzayo, Vabomere |
| Fisher & Paykel Healthcare INC | $117.45 | 2021-2022 | |
| Philips North America LLC | $117.24 | 2019 | |
| Verona Pharma, INC. | $116.99 | 2025 | Ohtuvayre |
| Genentech USA, INC. | $98.00 | 2019-2021 | |
| Electromed, INC. | $87.66 | 2021-2025 | Smartvest |
| Kerecis Limited | $86.25 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Ani Pharmaceuticals, INC. | $80.58 | 2024 | Purified Cortrophin Gel |
| Axsome Therapeutics, INC. | $78.56 | 2024 | Sunosi |
| Teva Pharmaceuticals USA, INC. | $52.70 | 2021 | |
| Gilead Sciences, INC. | $51.96 | 2021 | |
| Abbvie INC. | $47.13 | 2021 | |
| Sunovion Pharmaceuticals INC. | $46.38 | 2019 | |
| Mallinckrodt Enterprises LLC | $44.91 | 2019 | |
| Shionogi INC | $43.25 | 2020-2021 | |
| Veran Medical Technologies, INC. | $40.65 | 2019-2020 | |
| Baxter Healthcare | $39.14 | 2023 | Hillrom - Life 2000 Ventilation System |
| La Jolla Pharmaceutical Company | $36.07 | 2022 | |
| Medtronic, INC. | $32.50 | 2022 | |
| Vifor Pharma, INC. | $32.22 | 2024 | Zemaira |
| Inogen, INC. | $23.98 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Phadia US INC. | $21.22 | 2025 | Immunocap |
| Alexion Pharmaceuticals, INC. | $20.54 | 2022 | |
| Shire North American Group INC | $20.33 | 2019 | |
| Sandoz INC. | $19.27 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.32 | 2019 | |
| Circassia INC. | $16.28 | 2019 | |
| Nabriva Therapeutics, Plc | $15.13 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.24 | 2021 | |
| Covidien LP | $13.86 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$10,175.25 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Hull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.